Emcure Pharma Q2 | Profit rises 25% to ₹243 crore, revenue up 13% YoY

Emcure Pharmaceuticals Ltd on Tuesday (Nov 11) reported a 25.1% year-on-year rise in consolidated net profit to ₹243 crore for the quarter ended September 2025, compared with ₹194 crore in the same period last year.

Revenue from operations grew 13.4% year-on-year to ₹2,269.8 crore from ₹2,001.9 crore in Q2 FY25, driven by strong growth across key therapeutic segments and continued momentum in both domestic and international markets.

Earnings before interest, tax, depreciation, and amortisation (EBITDA) rose 25% to ₹475.4 crore from ₹380.3 crore in the year-ago quarter, while EBITDA margin improved to 21% from 19% a year earlier, aided by better product mix and cost efficiencies.

The company said its performance reflected robust traction in its India formulations business and healthy export demand. Emcure continues to maintain a diversified product portfolio across areas including gynaecology, cardiovascular, HIV antivirals, and pain management, and has been expanding its presence in emerging markets through new product launches and regulatory filings.

Management noted that the company remains focused on strengthening its branded portfolio and operational efficiency to drive sustainable growth in the coming quarters.

The shares of the company ended over 4% in the red in the session on Tuesday. The stock has fallen 6.4% in the year so far.

Catch live Q2 updates with CNBC-TV18.com's blog